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Despite extensive research, little progress has been made in glioblastoma therapy, owing in part to 
a lack of adequate preclinical in vivo models to study this disease. To mitigate this, primary patient‑
derived cell lines, which maintain their specific stem‑like phenotypes, have replaced established 
glioblastoma cell lines. However, due to heterogenous tumour growth inherent in glioblastoma, 
the use of primary cells for orthotopic in vivo studies often requires large experimental group sizes. 
Therefore, when using intracranial patient‑derived xenograft (PDX) approaches, it is advantageous to 
deploy imaging techniques to monitor tumour growth and allow stratification of mice. Here we show 
that stable expression of near‑infrared fluorescent protein (iRFP) in patient‑derived glioblastoma cells 
enables rapid, direct non‑invasive monitoring of tumour development without compromising tumour 
stemness or tumorigenicity. Moreover, as this approach does not depend on the use of agents like 
luciferin, which can cause variability due to changing bioavailability, it can be used for quantitative 
longitudinal monitoring of tumour growth. Notably, we show that this technique also allows 
quantitative assessment of tumour burden in highly invasive models spreading throughout the brain. 
Thus, iRFP transduction of primary patient‑derived glioblastoma cells is a reliable, cost‑ and time‑
effective way to monitor heterogenous orthotopic PDX growth.
Glioblastoma is the most common malignant intrinsic brain tumour in  adults1. Current treatment regimens, con-
sisting of surgical resection followed by radio- and chemotherapy, have limited efficacy in combating the disease, 
and this is reflected in a dismal prognosis for the  patients2,3. Improvement of therapeutic strategies is urgently 
needed to increase patient life expectancy and to reduce the disabling effects of the disease and its therapy. 
Development of novel therapies implicitly depends on reproducible and reliable models for preclinical studies 
in vitro and in vivo. However, experiments using orthotopic xenografts of established glioblastoma cell lines 
in immunocompromised mice to investigate effects of new therapies have many limitations. Most importantly, 
positive results observed in these preclinical studies have not been reproduced in subsequent clinical  studies4,5.
To better recapitulate human disease, the use of patient-derived glioblastoma stem-like cells (GSC) has gained 
increasing prominence in recent  years6,7. Several studies have demonstrated that patient-derived GSC cultured in 
serum-free neurobasal medium, supplemented with epidermal growth factor (EGF) and fibroblast growth factor 
(FGF), are more representative of primary glioblastoma than traditional, commercially-available glioblastoma 
cell  lines8,9. Nevertheless, it is not trivial to maintain the GSC population of surgical specimens using in vitro cell 
culture systems as stem cell growth varies due to plasticity, resulting in artificial selection of proliferating, rather 
than dormant GSC. Therefore, it is advantageous to study glioblastoma behaviour in vivo, as brain tissue provides 
the most appropriate microenvironment for maintenance of the stem signature of patient-derived xenografts 
(PDX)7. However, due to their intrinsic heterogeneity, orthotopic PDXs display a much greater range of growth 
rates between animal subjects compared to established glioblastoma cell  lines4,10. Although this variability is a 
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good reflection of the heterogeneity of the parental tumour, differences in growth characteristics, and therefore 
PDX size and the degree of dissemination at defined time points, lead to difficulties in quantifying and inter-
preting animal studies. Thus, large cohorts of animals are needed to achieve the necessary statistical power in 
these preclinical studies.
Currently, intra-vital bioluminescent imaging (BLI) with luciferase is commonly used to monitor xenograft 
 growth11. Yet, in vivo luciferase assays are limited to descriptive analysis since factors such as fluctuating substrate 
access to the target tissue result in variable luciferin bioavailability in tumours. Moreover, luciferase-based BLI 
does not allow for absolute quantification of the same tumour over time. Although magnetic resonance imaging 
(MRI) is ubiquitously used as clinical standard of care to diagnose brain tumours in humans, this technique has 
major drawbacks in preclinical settings. First of all, small animal MRIs are not widely available. Secondly, the 
procedure and its analysis are expensive as well as onerous for animals, requiring prolonged episodes of anaes-
thesia. Thirdly, MRIs often only measure indirect indicators of tumour pathology, such as focal brain oedema, 
which do not necessarily reflect the size and margins of the tumour itself.
To address these challenges, we have adapted a method of viral transduction to express iRFP, a protein with 
excitation and emission in the near-infrared spectrum, in patient-derived GSC, whilst maintaining their stem-
like phenotype, growth characteristics and individual susceptibility to drug treatments. Using these cells, we find 
that imaging iRFP is a reliable, rapid and cost-effective method to monitor tumour bulk and infiltrative growth 
of orthotopic glioblastoma models in vivo.
Materials and methods
Patient‑derived GSC and Cell culture reagents. Patient-derived E2, G1 and G7 glioblastoma stem-like 
cells (GSC), obtained from surgical resection specimens of anonymised patients as previously  described12,13, 
were kindly provided by Prof. Colin Watts. Serum-free medium for GSC was Advanced Dulbecco’s modified 
Eagle’s medium F12 (Thermo Fisher Scientific), supplemented with 2 mM glutamine, 4 μg/ml heparin (Sigma), 
1% B27 (Thermo Fisher Scientific), 0.5% N2 (Thermo Fisher Scientific), 20  ng/ml EGF and 10  ng/ml FGF 
(Thermo Fisher Scientific). GSC were cultured in a 37 °C incubator at 5%  CO2 and, when grown as monolayers, 
on Matrigel (Corning) pre-coated plates. For all experiments GSC were used up to ten passages after thawing. 
Cell lines were routinely tested for mycoplasma.
iRfp vector and retroviral transduction. As described previously, plasmids encoding iRFP IRES puro 
had been inserted into a pBABE  vector11. For GSC transduction HEK293-FT cells (4 × 106 in a 10  cm dish, 
cultured in high-glucose DMEM, complemented with 10% FCS and 2 mM glutamine) were transfected using 
4 μg polyethylenimine (PEI, Polysciences Inc., Warrington, USA) per μg plasmid DNA. The retroviral transfer 
vector plasmid pBABE iRFP IRES puro (kindly provided by Andreas  Hock11), packaging plasmid HIV-gag-pol 
(Addgene 14887) and envelope plasmid pUVSVG (Addgene 8454) DNA were mixed in a 4:2:1 ratio. DNA/PEI 
mixtures were incubated at room temperature for 10 to 15 min, prior to application on HEK293-FTs. 24 and 48 h 
later, virus containing supernatant was harvested and filtered (0.45 μM). Virus was extracted using Lenti-X con-
centrator (Clontech Takara) according to the manufacturer’s instructions. The virus containing pellet was resus-
pended in serum-free neurobasal medium and target cells were infected in the presence of 1 μg/ml polybrene 
(Sigma Aldrich). Two days following infection, cells were selected by growth in puromycin (E2 and G1 GSC: 
1 μg/ml, G7 GSC: 0.5 μg/ml, Sigma) containing medium. Drug resistant E2 and G7 GSC were further sorted by 
FACS to isolate the high signal expressing population of iRFP-labelled GSC prior to intracranial implantation. 
iRFP positivity of G1 GSC iRFP was confirmed by FACS (Supplemental Fig. 2a).
Cell proliferation and cell viability assay. GSC were seeded in three wells of a 6-well plate at a density 
of 5 × 104 cells per well. Cell number for each well was assessed using a haemocytometer 1, 3 and 6 days after 
seeding. A median was calculated for each time point. Cell count was normalised to day 1 (n = 3 independent 
repeats per cell line).
Cell death and cell confluence were determined using live-cell imaging in the IncuCyte Zoom (Sartorius). 
Therefore, 12 × 103 GSC per well were seeded in 96-well plates and treated with the described chemotherapeutic 
agents in the presence of 30 nM SYTOX Green (Life Technologies). Plates were applied to the IncuCyte imager 
at 37 °C in a humidified 95% air/ 5%  CO2 incubator. Over a period of 48 h, every hour two images were taken per 
well. Images were presented in green phase contrast at 10 × magnification and quantified using IncuCyte imaging 
analysis software (Sartorius). The following drugs were used: ABT737 (ApexBio, A8193), S63845 (Chemgood, 
C-1370), Actinomycin D (Calbiochem, 114666), Temozolomide (Sigma, T2577), Cisplatin (Selleck, S1166), 
Paclitaxel (Sigma, T7191). Percentage cell death was calculated by normalising against maximal cell death fol-
lowing treatment with 1 µM Actinomycin D, 10 µM ABT737 and 1 µM S63845 (100% cell death control, verified 
by visual inspection of IncuCyte images) (n = 3 independent repeats per cell line).
Cell migration assay. For migration assays, 6-well plates were coated with gelatine, subsequently cross-
linked with glutaraldehyde, quenched and equilibrated in serum-free GSC medium. GSC were seeded at a den-
sity of 8 × 104 per well, left to adhere and their movement was assessed over a 16-h period taking images every 
10 min using time-lapse video microscopy and manual cell tracking software (Fiji). For cell migration assays, 
three independent repeats per cell line were performed and 60 cells per repeat were manually tracked and quan-
tified using the chemotaxis plugin (Fiji).
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Figure 1.  Generation of iRFP-expressing glioblastoma stem-like cells. (a) Flow cytometric plots showing 
sorting for higher signal iRFP-overexpressing E2 and G7 GSC (upper panel: P3 = high signal iRFP positive cells; 
lower panel: iRFP +  = iRFP positive cells) (b) Representative images of monolayer E2, G1 and G7 GSC parental 
(upper panel) and iRFP-expressing cells (lower panel), respectively. (c) Proliferation assay of E2, G1 and G7 GSC 
counted at the indicated times after plating. Cell count was normalised to day 1. Error bars represent mean ± SD 
from n = 3 independent experiments.
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Neurosphere formation assay. GSC were seeded in uncoated 96-well plates at a density of 10 cells per 
well. Medium was refreshed every week. Spheres were left to grow for 14 days (G1 and G7 GSC) or 21 days (E2 
GSC) before manual scoring of the 60 inner wells (n = 3 independent repeats per cell line).
immunoblotting and antibodies. GSC were initially lysed and collected in RIPA buffer (50 mM Tris-
HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40), supplemented with Complete Protease Inhibitor (Roche) 
and PhosSTOP (Roche). Pierce BCA protein assay kit (Thermo Fisher Scientific) was used to determine pro-
tein concentration. Western blotting was performed by electrophoresis using 4–12% NuPage Bis-Tris protein 
gels (Thermo Fisher Scientific) followed by transfer to nitrocellulose membranes. After blocking in 5% non-fat 
dry milk, membranes were probed with primary antibodies (1:1,000 unless otherwise stated; SOX2 (Abcam 
#ab92494), Nestin (Abcam #ab22035), OLIG2 (R&D Systems #AF2418), GFAP (Santa Cruz #SC-6170) at 4 °C 
overnight. All membranes were incubated with α-tubulin serving as loading control (Sigma #T5168, 1:5,000) for 
one hour at room temperature. Membranes were incubated with Li-Cor secondary antibodies (IRDye 680RD 
donkey anti-mouse, IRDye 800CW donkey anti-rabbit, IRDye 800CW donkey anti-goat) for one hour at room 
temperature. Blots were imaged using Li-Cor Odyssey CLx (Li-Cor), acquired and processed using Image-Stu-
dio software (Li-Cor) and subsequently arranged using Adobe Illustrator.
intracranial xenografts. All mouse experiments were carried out in accordance with the Animals Act 
1986 (Scientific Procedures on living animals) and the regulatory guidelines of the EU Directive 2010 under pro-
ject licences PPL PB6CB58C4 and P4A277133 and ethical review (University of Glasgow). 7-week old, female 
CD1-nude mice (Charles River, UK) were orthotopically injected with 1 × 105 iRFP-labelled or unlabelled E2 
GSC or G7 GSC into the right striatum. Mice were monitored for the duration of the experiment and humanely 
sacrificed when they showed neurological (hemiparesis, paraplegia) or general symptoms (hunched posture, 
reduced mobility, and/or weight loss > 20%). To examine intracranial tumour growth in animals bearing iRFP-
positive tumour cells, mice were monitored by PEARL imaging (Li-Cor) acquired and processed using Image-
Studio software (Li-Cor). For imaging, mice were anaesthetised using isoflurane. Four weeks after tumour injec-
tion, a baseline scan was performed. Regular imaging was commenced 6 weeks (G7 GSC) or 8 weeks (E2 GSC) 
after tumour injection. The percentage change in the iRFP signal as a function of baseline scan was calculated 
according to the following equation:
Immunohistochemistry and in situ hybridisation. H&E staining and immunohistochemistry (IHC) 
for Ki67 (Abcam #ab16667) and SOX2 (Abcam #ab92494) were performed on formalin-fixed, paraffin embed-
ded brain sections (4 μm thick slices). For SOX2 IHC epitope retrieval was achieved by heating to 98 °C in pH6 
citrate buffer for 60 min before proceeding as per the manufacturer’s instructions with SOX2 antibody used at a 
dilution of 1:600 for E2 GSC and 1:400 for G7 GSC.
In situ hybridisation (ISH) analysis was performed using the RNAscope 2.5 LS (Brown, #322100) detection 
kit (Advanced Cell Diagnostics) on a Leica Bond Rx autostainer strictly adhering to manufacturer’s instruc-
tions. To selectively identify human cells, a human-specific PPIB-probe (Hs-PPIB, Advanced Cell Diagnostics, 
#313908) was used. Scanning and image analysis of both was conducted using Leica SlidePath and Halo (Indica 
Labs). Algorithms were optimised for each stain individually and automated, quantitative analysis undertaken 
with Halo software (Indica Labs).
(
newIRFPsignal−baselineiRFPsignal
baselineiRFPsignal
)
∗ 100.
Figure 2.  iRFP-expressing GSC retain stem-like features. (a) Representative images of neurosphere growth 
from E2, G1 and G7 GSC parental (upper panel) and iRFP-expressing cells (lower panel), respectively. 
Quantification of neurosphere formation capacity by E2 parental vs. iRFP GSC (p = 0.059), G1 parental versus 
iRFP GSC (p = 0.6427) and G7 parental versus iRFP GSC (p = 0.419). Error bars represent mean ± SEM from 
n = 3 independent experiments; ns, nonsignificant. (b) Immunoblotting for cell-line specific neural stem cell 
markers (SOX2, OLIG2, Nestin) and astrocyte lineage differentiation marker GFAP in E2, G1 and G7 GSC 
parental compared with paired iRFP GSC, respectively. Alpha-tubulin served as loading control. Representative 
loading controls given (E2 GSC: membrane for SOX2/Nestin, G1 GSC: membrane for GFAP, G7 GSC: 
membrane for GFAP). All loading controls are displayed with full-length blots in Supplemental Figure 1. (c) 
Random cell migration assay from E2, G1 and G7 GSC parental and iRFP-expressing GSC on cross-linked 
gelatine. Values are mean ± SEM. n = 180 cells per cell line, ns, nonsignificant (E2 GSC parental vs E2 GSC 
iRFP: p = 0.9189, G1 GSC parental vs. G1 GSC iRFP: p = 0.3625 G7 GSC parental vs. G7 GSC iRFP: p = 0.0650). 
(d) E2, G1 and G7 GSC parental and iRFP-expressing GSC treated with indicated drugs for 48 h and analysed 
for cell viability using an IncuCyte imager and SYTOX Green exclusion. Percentage cell death was calculated 
by normalising against maximal cell death (48 h-treatment with 1 µM Actinomycin D, 10 µM ABT737 and 
1 µM S6384). Error bars represent mean ± SEM from n = 3 independent experiments. No significant difference 
in response to treatment for all drugs tested in parental vs. iRFP matched counterparts (E2 GSC parental vs. 
E2 GSC iRFP: p ≥ 0.5186, G1 GSC parental vs. G1 GSC iRFP: p ≥ 0.1072, G7 GSC parental vs. G7 GSC iRFP: 
p ≥ 0.4302).
◂
5Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:15361  | https://doi.org/10.1038/s41598-020-72322-x
www.nature.com/scientificreports/
6Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:15361  | https://doi.org/10.1038/s41598-020-72322-x
www.nature.com/scientificreports/
Statistical analyses. All statistical analyses were executed with Prism Software version 8.4.2 (GraphPad, 
La Jolla, CA, USA). Significance of neurosphere formation and cell viability assays was calculated using Welch’s 
t-test. Significance of random cell migration assay was assessed using Mann–Whitney Test. For analysis of cor-
relation of Ki67 positivity, Hs-PPIB positivity and iRFP signal increase, single linear regression and Spearman’s 
r were used.
Results
Generation of iRFP‑expressing glioblastoma stem‑like cells. Near-infrared fluorescent proteins 
(iRFP) with excitation and emission in the 700 and 800  nm spectra allow tumour detection in deep tissues 
with only minimal interference from tissue  autofluorescence11. Since the use of iRFP in mouse models was first 
described in 2011, it has been shown to be a powerful and reliable tool to measure cell proliferation in vitro and 
in vivo11,14. We deployed a retroviral transduction approach to express iRFP in E2, G1 and G7 GSC, three primary 
patient-derived cell lines originally derived from fresh patient tissue as previously  described12,13. We tailored the 
protocol to reduce the number of manipulations so as to minimise effects on the heterogeneous nature of the 
GSC cultures. To avoid culturing GSC in FCS containing medium, which would drive cell differentiation, the 
iRFP-encoding retroviruses were resuspended in neurobasal medium. 48 h after infection, enrichment of iRFP-
expressing GSC was commenced using puromycin selection. Cell lines used for intracranial injections were 
further sorted for a cell population with higher signal intensity using fluorescence activated cell sorting (FACS) 
(Fig. 1a). Due to the infiltrative nature of E2 GSC xenograft growth, stricter gating parameters were applied to 
ensure subsequent detectability of the iRFP signal in vivo. There were no detectable differences between the 
morphology and proliferation rates of iRFP-expressing GSC and their matching parental controls (Fig. 1b,c).
iRFP‑expressing GSC retain stem‑like features. Cancer stem cells are understood to be the tumouri-
genic drivers of  glioblastoma15–17. Consequently, extensive research has been devoted to refining glioblastoma 
culturing methods so as to preserve the specific stem-like properties of patient tumour  specimens9,12,15,18. The 
microenvironment, including medium composition and culture conditions, inevitably affect the characteristics 
of stem cell  populations19. Their self-renewal capacity not only encourages rapid adaption to alterations in the 
microenvironment, but can also drive resistance to cancer  therapies20. Thus, we were keen to determine whether 
changes in stem cell characteristics had occurred after retroviral transduction. The capacity to form neuro-
spheres (as a proxy for tumour initiation) was conserved in the iRFP-expressing GSC, although a slight (but not 
statistically significant) decrease of neurosphere forming capacity was detectable in the E2 GSC iRFP (Fig. 2a). 
Furthermore, the expression of cell lineage-specific neural stem cell (SOX2, Nestin, OLIG2) and astrocytic dif-
ferentiation (GFAP) markers was maintained upon retroviral transduction and expression of iRFP, despite a 
moderate decrease in OIG2 and GFAP protein levels in E2 GSC (Fig. 2b). To investigate the migratory behaviour 
of iRFP-labelled GSC in comparison to their parental counterpart we deployed a random cell migration assay. 
No significant changes in cell migratory speed could be detected between the corresponding cell lines (Fig. 2c). 
Furthermore, we interrogated whether the cell-line specific cytostatic and cytotoxic response to a panel of stand-
ard chemotherapeutic agents was maintained (Fig. 2d, Supplemental Fig. 2b). We found that iRFP-labelled pri-
mary GSC retain a comparable level of resistance to established chemotherapeutics. Taken together, these data 
demonstrate that our approach to achieve iRFP expression is unlikely to influence GSC stem-like behaviour and 
response to treatment.
Quantitative imaging of iRfp‑expressing glioblastoma in vivo. We next determined whether iRFP 
was suitable for measuring glioblastoma growth in vivo. For this purpose, we generated orthotopic xenografts 
using E2 GSC iRFP and G7 GSC iRFP. When implanted into the right striatum of 7-week old CD1-nude mice, 
both iRFP-expressing cell lines retained the growth pattern characteristics and SOX2 expression of their paren-
tal counterparts (Supplemental Fig. 3a,b). While iRFP-expressing G7 GSC grew mainly as a solid tumour with 
invasive margins, E2 GSC iRFP disseminated throughout the brain as widely scattered tumour cells (formerly 
described as gliomatosis cerebri) to such an extent that the presence of a solid tumour at the injection site was 
not readily discernible (Fig. 3a). To date, no imaging tool has been capable of reliably detecting or quantitatively 
monitoring growth of highly invasive tumour xenografts, such as those engendered by E2 GSC. To determine 
whether iRFP expression enabled bona fide quantification of these highly disseminated tumours, we implanted 
1 × 105 iRFP-expressing E2 GSC into nude mice as before. Mice were initially scanned using a PEARL imager 
to establish a baseline, and this was performed 4 weeks after surgery to allow for sufficient recovery and wound 
healing. Images from single mice were acquired within 30s, followed by a short awakening and recovery phase. 
Based on previous studies using E2 GSC, we began imaging the mice at regular intervals from week 8 until 
clinical endpoint or 31 weeks after  surgery21,22. Analysis of the signal intensity over time revealed that a measur-
able increase in signal (with reference to the 4 week baseline) was detected as early as 16 weeks after surgery, 
delineating individual rates of signal increase for each animal (Fig. 3b,c). To investigate the utility of iRFP imag-
ing in PDX models growing as solid tumours with invasive margins, we used orthotopic G7 iRFP GSC xeno-
grafts. In this experiment, imaging commenced six weeks after tumour cell injection. Individual signal increase 
patterns for each of the three mice were detectable from 8 weeks following implantation, thus indicating that 
iRFP-expressing GSC may be used to monitor the growth of glioblastoma PDXs over an extended time course 
(Fig. 3d,e).
iRFP signal correlates with histological tumour burden. To determine whether the fluorescent 
signal emanating from iRFP-expressing GSC tumours correlated with histological tumour burden, we imaged 
brains bearing G7 GSC iRFP xenografts. We then fixed these brains ex vivo and stained them using H&E, thus 
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Figure 3.  Quantitative imaging of iRFP-expressing glioblastoma in vivo. (a) Representative images of 
haematoxylin and eosin (H&E), Ki67 and SOX2 immunohistochemistry of brain sections containing orthotopic 
tumours derived from intracranially injected G7 or E2 GSC iRFP. (b) E2 GSC iRFP were injected intracranially 
into five mice. iRFP signal increase was measured at indicated times (c,e). Pseudocolour representations of 
iRFP signal increase over time in individual mice bearing E2 or G7 GSC iRFP tumours, respectively, as detected 
by PEARL scans (700 nm channel). (d) G7 GSC iRFP were injected intracranially in three mice. iRFP signal 
increase measured at indicated times.
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Figure 4.  iRFP signal correlates with histological tumour burden. (a) Representative ex vivo PEARL and Odyssey scans of G7 
GSC iRFP tumour in a mouse brain after resection (left), and on coronar section (middle, denoted by white line in left image) in 
comparison to matching H&E stain (right). 700 nm scan (red) was used to visualise the tumour, brain autofluorescence was detected 
in 800 nm channel (green). (b) G7 GSC iRFP signal detected with PEARL imager (a.u., arbitrary units) corresponds with calculated 
spherical tumour volume  (mm3), extrapolated from mean diameter in H&E stains. (c) Upper panel: Odyssey scans of coronar sections 
from E2 GSC iRFP bearing mice. 700 nm scan (red) was used to visualise tumours, brain autofluorescence was detected in 800 nm 
channel (green). Middle and lower panel: corresponding Ki67 staining and magnification. (d) Simple linear regression correlating E2 
GSC iRFP signal with percentage of Ki67 positive tumour cells and Hs-PPIB-positive tumour cells in five mice, quantified with Halo 
analysis software (Ki67: p = 0.0755, Spearman correlation r = 0.9, Hs-PPIB: p = 0.0773, Spearman correlation r = 1).
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allowing comparison of the fluorescence and histological fields. We found that in mice implanted with G7 GSC, 
iRFP fluorescence faithfully delineated the extent of intraparenchymal spread that had been detected using iRFP 
imaging. Strikingly, imaging was sufficiently sensitive to illustrate the central core necrosis that was evident fol-
lowing H&E staining (Fig. 4a). Since G7 iRFP tumours grew approximately spherically in vivo, we extrapolated 
tumour volume from the mean diameter in H&E and correlated it with the absolute iRFP signal measured at 
the final imaging obtained before endpoint. Notably, the fluorescent signal emanating from iRFP-expressing G7 
GSC tumour bearing mice was highly concordant with the calculated tumour volume (Fig. 4b). As highly inva-
sive models such as E2 GSC do not permit measurement of a defined tumour bulk, we sought to examine the 
accuracy with which iRFP signal intensity represented tumour burden. Using the proportion of Ki67-positive 
cells across the brain section as a proxy, we observed that the burden of disseminated E2 GSC tumour cells 
varied substantially between animals, similar to the intravital imaging data (Fig. 4c). Moreover, we found that 
the relative iRFP signal increase at endpoint correlated strongly with the relative prevalence of Ki67-positive 
cells (Spearman correlation r = 0.9) (Fig. 4d). To evaluate the robustness of this correlation, we conducted in situ 
hybridisation for human-specific PPIB. Affirmingly, we observed a strong correlation between the relative final 
iRFP signal increase and the relative prevalence of human-specific PPIB (Spearman correlation r = 1). Taking 
into account the limited number of animals, the observed trend towards statistical significance for both mark-
ers (Ki67: p = 0.0755, PPIB: p = 0.0773) supports the reliability of the model. In summary, our data demonstrate 
that near-infrared labelling of highly invasive primary patient-derived glioblastoma cells is a powerful tool to 
quantitatively monitor their growth in vivo.
Discussion
Reporter gene-based technologies, such as luciferase-based bioluminescence, are widely used but have particular 
limitations especially with regard to quantitative longitudinal assessment of tumour xenograft growth. In this 
paper we show that the use of cell lines stably expressing iRFP overcomes many of these limitations. We have 
demonstrated that it is feasible to manipulate primary glioblastoma stem-like cells by stably overexpressing the 
near-infrared fluorescent protein iRFP without overtly affecting their particular stem-like properties. Signal 
intensity is consistent and reliable over time and permits monitoring of orthotopic tumour growth in vivo with 
a high degree of accuracy. This is especially valuable for highly invasive cell lines such as E2 GSC, which can-
not be detected or quantified with conventional imaging methods such as MRI. As iRFP enables cost-effective, 
repeated and comparatively high throughput non-invasive imaging of mice bearing orthotopic glioblastoma 
PDX, it could be used to determine individual treatment start dates for mice when they reach a certain threshold, 
mimicking more closely the clinical scenario. Additionally, this method may also be used to stratify mice into 
cohorts depending on their actual biological tumour burden. This application serves to reduce the number of 
mice needed for statistical power in heterogenous primary glioblastoma PDX-models.
Use of additional patient-derived PDX would help to further validate the general applicability of our model. 
A further advantage of iRFP expressing tumours is the ability to FACS-sort tumour cells without the need for 
antibody labelling, enhancing cell viability and leaving cell surface molecules unperturbed.
In summary, our results show that iRFP serves as a reliable and sensitive tool to monitor intracranial tumour 
growth in both highly invasive and more localised primary glioblastoma orthotopic xenograft models without 
affecting their phenotypes. This new technique provides significant benefits for the design, execution and analysis 
of in vivo studies using glioblastoma PDX.
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